Literature DB >> 20974503

Synthesis and biological evaluation of N-substituted-3,5-diphenyl-2-pyrazoline derivatives as cyclooxygenase (COX-2) inhibitors.

Rossella Fioravanti1, Adriana Bolasco, Fedele Manna, Francesca Rossi, Francisco Orallo, Francesco Ortuso, Stefano Alcaro, Roberto Cirilli.   

Abstract

Eighteen new 1-N-substituted-3,5-diphenyl-2-pyrazoline derivatives have been synthesized and cyclooxygenase (COX-1 and COX-2) inhibitory activities have been evaluated. The results of these biological assays showed that all of new derivatives are not endowed with improved anti-inflammatory activity against COX-1, but some of them showed a good activity against COX-2. To evaluate the binding mode of the most significative compounds (2d, 2f, 2g and 2k) docking studies were carried out. These studies confirmed biological data, in fact these compounds were able to fit into the active site of COX-2.
Copyright © 2010 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20974503     DOI: 10.1016/j.ejmech.2010.10.005

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  11 in total

1.  Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors.

Authors:  V C Di Maio; V Cento; C Mirabelli; A Artese; G Costa; S Alcaro; C F Perno; F Ceccherini-Silberstein
Journal:  Antimicrob Agents Chemother       Date:  2014-03-03       Impact factor: 5.191

2.  Design and efficient synthesis of pyrazoline and isoxazole bridged indole C-glycoside hybrids as potential anticancer agents.

Authors:  Priti Kumari; Vishnu S Mishra; Chintam Narayana; Ashish Khanna; Anindita Chakrabarty; Ram Sagar
Journal:  Sci Rep       Date:  2020-04-20       Impact factor: 4.379

3.  Pyrazoles and Pyrazolines as Anti-Inflammatory Agents.

Authors:  Martha Mantzanidou; Eleni Pontiki; Dimitra Hadjipavlou-Litina
Journal:  Molecules       Date:  2021-06-05       Impact factor: 4.411

4.  Carbonic Anhydrase Inhibition with Sulfonamides Incorporating Pyrazole- and Pyridazinecarboxamide Moieties Provides Examples of Isoform-Selective Inhibitors.

Authors:  Andrea Angeli; Victor Kartsev; Anthi Petrou; Mariana Pinteala; Volodymyr Brovarets; Roman Vydzhak; Svitlana Panchishin; Athina Geronikaki; Claudiu T Supuran
Journal:  Molecules       Date:  2021-11-20       Impact factor: 4.411

Review 5.  Structure-activity relationships for the synthesis of selective cyclooxygenase 2 inhibitors: an overview (2009-2016).

Authors:  G Carullo; F Galligano; F Aiello
Journal:  Medchemcomm       Date:  2016-12-12       Impact factor: 3.597

6.  Design, Synthesis, and Evaluation of New Tripeptides as COX-2 Inhibitors.

Authors:  Ermelinda Vernieri; Isabel Gomez-Monterrey; Ciro Milite; Paolo Grieco; Simona Musella; Alessia Bertamino; Ilaria Scognamiglio; Stefano Alcaro; Anna Artese; Francesco Ortuso; Ettore Novellino; Marina Sala; Pietro Campiglia
Journal:  J Amino Acids       Date:  2013-02-26

7.  ZnO nanoparticles as an efficient, heterogeneous, reusable, and ecofriendly catalyst for four-component one-pot green synthesis of pyranopyrazole derivatives in water.

Authors:  Harshita Sachdeva; Rekha Saroj
Journal:  ScientificWorldJournal       Date:  2013-10-24

8.  Synthesis, Characterization, and Cytotoxicity of Some New 5-Aminopyrazole and Pyrazolo[1,5-a]pyrimidine Derivatives.

Authors:  Ashraf S Hassan; Taghrid S Hafez; Souad A Osman
Journal:  Sci Pharm       Date:  2014-10-24

9.  Anti-inflammatory and antimicrobial activities of novel pyrazole analogues.

Authors:  R Surendra Kumar; Ibrahim A Arif; Anis Ahamed; Akbar Idhayadhulla
Journal:  Saudi J Biol Sci       Date:  2015-07-29       Impact factor: 4.219

10.  Pyrazolo[4,3-c]pyridine Sulfonamides as Carbonic Anhydrase Inhibitors: Synthesis, Biological and In Silico Studies.

Authors:  Andrea Angeli; Victor Kartsev; Anthi Petrou; Boris Lichitsky; Andrey Komogortsev; Mariana Pinteala; Athina Geronikaki; Claudiu T Supuran
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.